Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer.

Inclusion criteria

• Women ≥ 18 years old and ≤ 50 years old.
• Non-menopausal status at time of diagnosis of breast cancer (self-reporting).
• Patient with breast cancer (uni or bilateral):

• treated at the Institut Bergonié by chemotherapy (+/- targeted/immunotherapy) and surgical treatment (conservative or not) and/or hormone therapy and/or radiotherapy
• who completed their treatment at least 6 months ago including end of treatment with Herceptin but with the exception for ongoing hormone therapy
• in complete remission
• Non-immunosuppressed patient.
• Voluntarily signed and dated written informed consent prior to any study specific procedure.
• Patient affiliated to a social security in compliance with Article 1121-11 of the French Public Health Code.

Exclusion criteria

• Patients with a history of or declared autoimmune disease or immune system deficiency or undergoing immunosuppressive treatment. A 6-month washout is required.
• Patients undergoing or planning to undergo peeling treatment or laser/ultrasound-based or botox treatment or hyaluronic acid injections during the study or having had one of these treatments in the 6 months preceding the study.
• Patients showing cutaneous disorders, inflammation or infection (acne, herpes labialis, scars…) at the treatment site or near to this site.
• Patients having a known hypersensibility to lidocaine and/or amide local anaesthetic agents or hyaluronic acid and/or proteins from gram-positive bacteria, or with a history of severe allergy or anaphylactic shock.
• Patients with a history of streptococcal disease (recurrent sore throat, rheumatic fever)
• Patients with autoimmune or cardiac diseases (i.e. heart conduction disorders) and/or undergoing treatment for heart diseases (beta-blockers).
• Patients with hepatocellular insufficiency and/or undergoing treatment for liver disease.
• Patients suffering from epilepsy not controlled by a treatment or porphyria.
• Patients with a tendency to develop hypertrophic scars.
• Patients with severe, ongoing and/or uncontrolled disease that may pose a health risk to the patient during the study and/or may have an impact on the study assessments.
• Patients receiving or planning to receive high dose Vitamin E, aspirin, anti-inflammatories, or anti-coagulant during the week preceding each injection
• Patients receiving any long-term medical treatment or any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the patient at undue risk.
• Patients under guardianship/tutorship.
• Pregnant women or breastfeeding mothers.